anti-b7-h3 antibody

A B7-H3, antibody technology, applied in the direction of antibodies, antibody medical components, anti-tumor drugs, etc., can solve problems such as changes in antibody performance

Active Publication Date: 2016-10-12
DAIICHI SANKYO CO LTD
View PDF14 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Although antibodies are specific for the same antigen, antibody performance may vary due to differences in epitopes or antibody sequences

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • anti-b7-h3 antibody
  • anti-b7-h3 antibody
  • anti-b7-h3 antibody

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0181] 2. Preparation of Anti-B7-H3 Antibody

[0182] Anti-B7-H3 antibodies of the present invention can be obtained by immunizing animals with B7-H3 or any polypeptide selected from the amino acid sequence of B7-H3 according to conventional methods, and collecting and purifying the antibodies produced in vivo. The biological species of B7-H3 used as an antigen is not limited to humans, and animals can be immunized with B7-H3 derived from animals other than humans, such as mice or rats. In this case, antibodies applicable to human diseases can be selected by testing the cross-reactivity of the antibodies with the resulting binding of heterologous B7-H3 and human B7-H3.

[0183] Furthermore, according to known methods (for example, Kohler and Milstein, Nature, (1975) 256, pp. 495-497; Kennet, R. ed., Monoclonal Antibody, pp. 365-367, Prenum Press, N.Y. (1980)) , Monoclonal antibodies can be obtained by fusing antibody-producing cells that produce anti-B7-H3 antibodies with mye...

Embodiment 1

[0350] Example 1. Preparation of plasmids

[0351] 1)-1 Preparation of human B7-H3 expression vector

[0352] 1)-1-1 Preparation of expression vector of full-length human B7-H3 variant 1

[0353] Using cDNA synthesized from total RNA of LNCaP cells (American Type Culture Collection (ATCC)) as a template, and also using the following primer set, a PCR reaction was performed to amplify the cDNA encoding human B7-H3 variant 1 :

[0354] Primer 1:

[0355] 5'-ctatagggagacccaagctggctagcatgctgcgtcggcggggcag-3' (SEQ ID NO: 1 in the Sequence Listing); and

[0356] Primer 2:

[0357] 5'-aacgggccctctagactcgagcggccgctcaggctatttcttgtccatcatcttctttgctgtcag-3' (SEQ ID NO: 2 in the sequence listing).

[0358] Subsequently, the PCR product thus obtained was purified using MagExtractor PCR & Gel cleanup (TOYOBO, Co., Ltd.). Then, the PCR product was digested with restriction enzymes (NheI and NotI), followed by purification using MagExtractor PCR & Gel cleanup (TOYOBO, Co., Ltd.). The p...

Embodiment 2

[0419] Example 2. Preparation of monoclonal antibodies and screening of antibodies

[0420] 2)-1 Immunization

[0421] 4-6 week-old BALB / cAnNCrlCrlj mice (Charles River Laboratories Japan, Inc.), FcgRII KO mice (Taconic, Inc., IBL Co., Ltd.) or GANP mice (Transgenic, Inc.) were used. On days 0, 7, 15 and 24, at 5 x 10 6 LNCaP cells, MCF7 cells (ATCC) or AsPC1 cells (ATCC) detached with ethylenediaminetetraacetic acid (Invitrogen Corporation) were administered subcutaneously to the dorsal region of each mouse at a dose of 2 cells / mouse. On day 31, with 5 x 10 6 A dose of each cell was administered intravenously to each mouse. On day 34, spleens were excised from each mouse and used to prepare hybridomas.

[0422] 2)-2 Preparation of hybridomas

[0423] Using PEG 4000 (manufactured by IBL Co., Ltd.), spleen cells and mouse myeloma P3X63Ag8U.1 cells (ATCC) were subjected to cell fusion, whereby hybridomas were prepared.

[0424] As a result, the following clones were establ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to antibodies that have a therapeutic effect on tumors. That is, the present invention relates to antibodies that bind to B7-H3 to exhibit antitumor activity. An object of the present invention is to provide a drug having a therapeutic effect on tumors. By obtaining an anti-B7-H3 antibody that binds to B7-H3 to exhibit anti-tumor activity, a pharmaceutical composition for treating tumors comprising the antibody and the like is obtained.

Description

technical field [0001] The present invention relates to antibodies that bind to B7-H3 and are useful as therapeutic and / or preventive agents for tumors, and also to methods for treating and / or preventing tumors using the antibodies. Background technique [0002] B7-H3 is a protein with a single-pass transmembrane structure (Non-Patent Document 1). The N-terminal extracellular domain of B7-H3 contains 2 variants. Variant 1 contains V-like and C-like Ig domains at each of 2 sites, respectively, and variant 2 contains V-like and C-like Ig domains at 1 site, respectively . The C-terminal intracellular domain of B7-H3 contains 45 amino acids. [0003] TLT-2 having a single-pass transmembrane structure has been reported as a receptor of B7-H3 (Non-Patent Document 2). However, it has also been reported that TLT-2 is not a receptor for B7-H3 (Non-Patent Document 3). According to a previous report, when the receptor binds to B7-H3, it enhances the activation of CD8-positive T ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/09A61K38/00A61K39/395A61P35/00C07K16/28C12N1/15C12N1/19C12N1/21C12N5/10C12N15/02C12P21/02C12P21/08
CPCC07K16/30C07K2317/732C07K2317/734C07K2317/24C07K2317/73C07K16/2827A61P35/00C07K16/28A61K39/395C07K16/42A61K39/39558A61K45/06A61K2039/505C07K2317/40C07K2317/92
Inventor 高桥秀松冈达司村上贤二泷泽刚广谷贤志浦野敦司福地圭介矢泽光弘
Owner DAIICHI SANKYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap